Eli Lilly and Company

AI Summary

Eli Lilly discovers, develops, manufactures, and sells prescription medicines globally. Their product portfolio spans diabetes drugs (Humalog, Mounjaro, Trulicity), obesity treatments (Zepbound), cancer therapies (Verzenio, Jaypirca), immunology drugs (Taltz, Olumiant), and Alzheimer's treatments (Kisubla). The company operates manufacturing facilities and research labs, and recently began licensing its AI drug discovery platform (TuneLab) to other biotech firms [Yahoo Finance].

Eli Lilly is a major pharmaceutical company with a $910.8 billion market cap [Yahoo Finance], known for developing drugs for diabetes, obesity, cancer, and immunology. The company is riding a massive wave of growth driven by its obesity and diabetes medications Mounjaro and Zepbound, which now generate roughly $13 billion combined per quarter [GuruFocus]. Recent positive clinical trial data and a $4.50 billion manufacturing expansion [Yahoo Finance] signal the company's commitment to this lucrative market, though this concentration creates significant execution risk.

Eli Lilly is in exceptional financial health, posting explosive growth and strong profitability metrics [Yahoo Finance].

Recent News

• Eli Lilly Expands TuneLab Access As AI Partnerships Shape R&D Outlook

  Simply Wall St· 2026-05-20

• Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

  Yahoo Finance· 2026-05-20

• Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault

  Yahoo Finance· 2026-05-20

• Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

  Yahoo Finance· 2026-05-20

• Supreme Court Ruling Puts Eli Lilly Medicaid Risks And Dividend In Focus

  Simply Wall St· 2026-05-18

• If You Hold This Healthcare ETF, You’re Losing Big

  Yahoo Finance· 2026-05-19